首页> 美国卫生研究院文献>other >Comparative efficacy and safety of lipid-lowering agents in patients with hypercholesterolemia

【2h】

Comparative efficacy and safety of lipid-lowering agents in patients with hypercholesterolemia

机译：降血脂药在高胆固醇血症患者中的比较疗效和安全性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

获取外文期刊封面目录资料

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Background:The comparative efficacy and safety of PCSK9 inhibitors, statins, and ezetimibe to lower lipid levels in patients with hypercholesterolemia remain unknown. We aimed to investigate the benefits and harms of the lipid-lowering agents in these patients.

机译：背景：高胆固醇血症患者中PCSK9抑制剂，他汀类药物和依折麦布降低血脂水平的比较疗效和安全性尚不清楚。我们旨在研究降脂药在这些患者中的利弊。

著录项

期刊名称 other
作者
Zonglei Zhao; Song Du; Shuxin Shen; Ping Luo; Shoukun Ding; Guanggong Wang; Lixia Wang;
展开▼
作者单位

展开▼
年(卷),期 -1(98),6
年度 -1
页码 e14400
总页数 12
原文格式 PDF
正文语种
中图分类
关键词
cardiovascular events hypercholesterolemia low-density lipoprotein meta-analysis PCSK9 inhibitors;

机译：心血管事件;高胆固醇血症;低密度脂蛋白;荟萃分析;PCSK9抑制剂;

相似文献

外文文献
中文文献
专利

1. Comparative efficacy and safety of lipid-lowering agents in patients with hypercholesterolemia: A frequentist network meta-analysis [J] . Zhao Zonglei, Du Song, Shen Shuxin, Medicine. . 2019,第6期

机译：高胆固醇血症患者脂降低剂的比较疗效和安全性：频繁的网络荟萃分析
2. Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale [J] . Tamio Teramoto, Akira Kondo, Arihiro Kiyosue, Lipids in Health Disease . 2017,第1期

机译：Alirocumab在高胆固醇血症患者中的功效和安全性没有充分控制非他汀类脂质降低治疗或他汀类药物的最低强度：奥德赛尼格研究设计和理论
3. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: Design and rationale of the ODYSSEY FH studies [J] . KasteleinJ.J.P., RobinsonJ.G., FarnierM., Cardiovascular drugs and therapy . 2014,第3期

机译：Alirocumab对目前尚无降脂治疗不能充分控制的杂合性家族性高胆固醇血症患者的疗效和安全性：ODYSSEY FH研究的设计和原理
4. Efficacy and safety of SPRINT and STAR protocol on Malaysian critically-ill patients [C] . Nurhamim Ahamad, Normy Razak, Ummu Jamaluddin, 2016 IEEE-EMBS Conference on Biomedical Engineering and Sciences . 2016

机译：SPRINT和STAR方案对马来西亚重症患者的疗效和安全性
5. Development and psychometric analysis of a Lipid-Lowering Therapy Quality of Life Scale for patients with hypercholesterolemia. [D] . Coombs, Vicki J. 2005

机译：高胆固醇血症患者降脂治疗生活质量量表的研制和心理计量学分析。
6. Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale [O] . Tamio Teramoto, Akira Kondo, Arihiro Kiyosue, 2017

机译：使用非他汀类降脂治疗或他汀类药物最低强度不能充分控制的高胆固醇血症患者使用alirocumab的疗效和安全性：ODYSSEY NIPPON研究设计和原理
7. Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of the ODYSSEY FH Studies [O] . John J. P. Kastelein, Jennifer G. Robinson, Michel Farnier, 2014

机译：Alirocumab对目前尚无降脂治疗不能充分控制的杂合子家族性高胆固醇血症患者的疗效和安全性：ODYSSEY FH研究的设计和原理

Comparative efficacy and safety of lipid-lowering agents in patients with hypercholesterolemia

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅